Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011–2016)

References

• Lindskog S. Structure and mechanism of carbonic anhydrase. Pharmacol Ther. 1997;74(1):1–20.
   PubMed Web of Science ®Google Scholar
• Kannan KK, Notstrand B, Fridborg K, et al. Crystal structure of human erythrocyte carbonic anhydrase B. Three-dimensional structure at a nominal 2.2-A resolution. Proc Natl Acad Sci. 1975;72(1):51–55.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett. 2010;20(12):3467–3474.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7(2):168–181.
   PubMed Web of Science ®Google Scholar
• Chegwidden WR, Carter ND, Edwards YH. The carbonic anhydrases: new horizons. Birkhauser: Springer Science & Business Media; 2000.
   Google Scholar
• Frost SC, McKenna R. Carbonic anhydrase: mechanism, regulation, links to disease, and industrial applications. Dordrecht: Springer Science & Business Media; 2013.
   Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2015;31(3):345–360.
   Google Scholar
• Imtaiyaz Hassan M, Shajee B, Waheed A, et al. Structure, function and applications of carbonic anhydrase isozymes. Bioorg Med Chem. 2013 Mar 15;21(6):1570–1582.
   PubMed Web of Science ®Google Scholar
• Berthelsen PG, Dich-Nielsen JO. Respiratory function and carbonic anhydrase inhibition. Intensive Care Med. 1987;13(5):323–327.
   PubMed Web of Science ®Google Scholar
• Adeva-Andany MM, Fernández-Fernández C, Sánchez-Bello R, et al. The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans. Atherosclerosis. 2015;241(1):183–191.
   PubMed Web of Science ®Google Scholar
• Müller Weg, Schröder HC, Tolba E, et al. Mineralization of bone-related SaOS-2 cells under physiological hypoxic conditions. FEBS J. 2016;283(1):74–87.
   PubMed Web of Science ®Google Scholar
• De Simone G, Supuran CT. Carbonic anhydrase IX: biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta. 2010;1804(2):404–409.
   PubMed Web of Science ®Google Scholar
• Alterio V, Hilvo M, Di Fiore A, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci. 2009;106(38):16233–16238.
   PubMed Web of Science ®Google Scholar
• Schlue WR, Deitmer JW. Ionic mechanisms of intracellular pH regulation in the nervous system. Ciba Found Symp. 1988;139:47–69.
   PubMedGoogle Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10(10):767–777.
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Parkkila S, Pastorek J, et al. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem. 2004;19(3):199–229.
   PubMed Web of Science ®Google Scholar
• Pinard MA, Mahon B, McKenna R. Probing the surface of human carbonic anhydrase for clues towards the design of isoform specific inhibitors. BioMed Res Int. 2015;2015:e453543.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev. 2003;23(2):146–189.
   PubMed Web of Science ®Google Scholar
• Kannan KK, Ramanadham M, Jones TA. Structure, refinement, and function of carbonic anhydrase isozymes: refinement of human carbonic anhydrase I. Ann N Y Acad Sci. 1984;429:49–60.
   PubMed Web of Science ®Google Scholar
• Avvaru BS, Kim CU, Sippel KH, et al. A short, strong hydrogen bond in the active site of human carbonic anhydrase II. Biochem. 2010;49(2):249–251.
   PubMed Web of Science ®Google Scholar
• Mallis RJ, Poland BW, Chatterjee TK, et al. Crystal structure of S-glutathiolated carbonic anhydrase III. FEBS Lett. 2000;482(3):237–241.
   PubMed Web of Science ®Google Scholar
• Stams T, Nair SK, Okuyama T, et al. Crystal structure of the secretory form of membrane-associated human carbonic anhydrase IV at 2.8-A resolution. Proc Natl Acad Sci. 1996;93(24):13589–13594.
   PubMed Web of Science ®Google Scholar
• Boriack-Sjodin PA, Heck RW, Laipis PJ, et al. Structure determination of murine mitochondrial carbonic anhydrase V at 2.45-A resolution: implications for catalytic proton transfer and inhibitor design. Proc Natl Acad Sci. 1995;92(24):10949–10953.
   PubMed Web of Science ®Google Scholar
• Pilka ES, Kochan G, Oppermann U, et al. Crystal structure of the secretory isozyme of mammalian carbonic anhydrases CA VI: implications for biological assembly and inhibitor development. Biochem Biophys Res Commun. 2012;419(3):485–489.
   PubMed Web of Science ®Google Scholar
• Whittington DA, Waheed A, Ulmasov B, et al. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc Natl Acad Sci. 2001;98(17):9545–9550.
   PubMed Web of Science ®Google Scholar
• Di Fiore A, Monti SM, Hilvo M, et al. Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. Proteins. 2009;74(1):164–175.
   PubMed Web of Science ®Google Scholar
• Whittington DA, Grubb JH, Waheed A, et al. Expression, assay, and structure of the extracellular domain of murine carbonic anhydrase XIV: implications for selective inhibition of membrane-associated isozymes. J Biol Chem. 2004;279(8):7223–7228.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235–242.
   PubMed Web of Science ®Google Scholar
• Moeker J, Mahon BP, Bornaghi LF, et al. Structural insights into carbonic anhydrase IX isoform specificity of carbohydrate-based sulfamates. J Med Chem. 2014;57(20):8635–8645.
   PubMed Web of Science ®Google Scholar
• Mahon BP, Lomelino CL, Ladwig J, et al. Mapping selective inhibition of the cancer-related carbonic anhydrase IX using structure-activity relationships of Glucosyl-based sulfamates. J Med Chem. 2015;58(16):6630–6638.
   PubMed Web of Science ®Google Scholar
• Mahon BP, Hendon AM, Driscoll JM, et al. Saccharin: a lead compound for structure-based drug design of carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2015;23(4):849–854.
   PubMed Web of Science ®Google Scholar
• Tu CK, Silverman DN, Forsman C, et al. Role of histidine 64 in the catalytic mechanism of human carbonic anhydrase II studied with a site-specific mutant. Biochem. 1989;28(19):7913–7918.
   PubMed Web of Science ®Google Scholar
• Duda D, Tu C, Qian M, et al. Structural and kinetic analysis of the chemical rescue of the proton transfer function of carbonic anhydrase II. Biochem. 2001;40(6):1741–1748.
   PubMed Web of Science ®Google Scholar
• Fisher Z, Hernandez Prada JA, Tu C, et al. Structural and kinetic characterization of active-site histidine as a proton shuttle in catalysis by human carbonic anhydrase II. Biochem. 2005;44(4):1097–1105.
   PubMed Web of Science ®Google Scholar
• Fisher SZ, Maupin CM, Budayova-Spano M, et al. Atomic crystal and molecular dynamics simulation structures of human carbonic anhydrase II: insights into the proton transfer mechanism. Biochem. 2007;46(11):2930–2937.
   PubMed Web of Science ®Google Scholar
• Aggarwal M, Kondeti B, Tu C, et al. Structural insight into activity enhancement and inhibition of H64A carbonic anhydrase II by imidazoles. IUCrJ. 2014;1(Pt 2):129–135.
   PubMed Web of Science ®Google Scholar
• McBain EH. Diagnosis and treatment of glaucoma; a review of recent developments. Calif Med. 1954;81(3):231–234.
   PubMedGoogle Scholar
• Swenson ER. New insights into carbonic anhydrase inhibition, vasodilation, and treatment of hypertensive-related diseases. Curr Hypertens Rep. 2014;16(9):467.
   PubMed Web of Science ®Google Scholar
• Kemp G, Kemp D. Diuretics. Am J Nurs. 1978;78(6):1006–1010.
   PubMed Web of Science ®Google Scholar
• Ruusuvuori E, Huebner AK, Kirilkin I, et al. Neuronal carbonic anhydrase VII provides GABAergic excitatory drive to exacerbate febrile seizures. EMBO J. 2013;32(16):2275–2286.
   PubMed Web of Science ®Google Scholar
• Pinard MA, Boone CD, Rife BD, et al. Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases. Bioorg Med Chem. 2013;21(22):7210–7215.
   PubMed Web of Science ®Google Scholar
• Ivanova J, Leitans J, Tanc M, et al. X-ray crystallography-promoted drug design of carbonic anhydrase inhibitors. Chem Commun. 2015;51(33):7108–7111.
   PubMed Web of Science ®Google Scholar
• Kanski JJ. Carbonic anhydrase inhibitors and osmotic agents in glaucoma. Br J Ophthalmol. 1968;52(8):642–643.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(4):423–431.
   PubMed Web of Science ®Google Scholar
• Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649–654.
   PubMed Web of Science ®Google Scholar
• Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000;19(1):87–112.
   PubMed Web of Science ®Google Scholar
• Maren TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev. 1967;47(4):595–781.
   PubMed Web of Science ®Google Scholar
• Poulsen S-A, Wilkinson BL, Innocenti A, et al. Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. Bioorg Med Chem Lett. 2008;18(16):4624–4627.
   PubMed Web of Science ®Google Scholar
• More RH, McMillan GC, Duff GL. The pathology of sulfonamide allergy in man. Am J Pathol. 1946;22(4):703–735.
   Web of Science ®Google Scholar
• Wulf NR, Matuszewski KA. Sulfonamide cross-reactivity: is there evidence to support broad cross-allergenicity? Am J Health-Syst Pharm. 2013;70(17):1483–1494.
   PubMed Web of Science ®Google Scholar
• Aggarwal M, McKenna R. Update on carbonic anhydrase inhibitors: a patent review (2008-2011). Expert Opin Ther Pat. 2012;22(8):903–915.
   PubMed Web of Science ®Google Scholar
• Schmidl D, Schmetterer L, Garhöfer G, et al. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015;31(2):63–77.
   PubMed Web of Science ®Google Scholar
• Cholkar K, Trinh HM, Pal D, et al. Discovery of novel inhibitors for the treatment of glaucoma. Expert Opin Drug Discov. 2015;10(3):293–313.
   PubMed Web of Science ®Google Scholar
• Karavas E, Koutris E, Samara V, et al. Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof. US2015080385. 2015.
   Google Scholar
• Kim NN, Mcvicar WK, Mccauley TG. Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure. CN102933220. 2013.
   Google Scholar
• Combination of adenosine derivative and carbonic anhydrase inhibitor and beta-receptor blocker. JP2012250949. 2012.
   Google Scholar
• Yadav RP, Kadam SN, Bhagit AA, et al. Method for the synthesis of bifunctional cerium oxide nanoparticle with enhanced antioxidant and carbonic anhydrase inhibitory activity. IN1948MU2015. 2015.
   Google Scholar
• Ivanov S, Liao S-Y, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001;158(3):905–919.
   PubMed Web of Science ®Google Scholar
• Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001;19(16):3660–3668.
   PubMed Web of Science ®Google Scholar
• Chamie K, Klöpfer P, Bevan P, et al. Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: data from the phase III ARISER clinical trial. Urol Oncol Semin Orig Investig. 2015;33(5):204.e25-204.e33.
   Google Scholar
• Huang W-J, Jeng Y-M, Lai H-S, et al. Expression of hypoxic marker carbonic anhydrase IX predicts poor prognosis in resectable hepatocellular carcinoma. PLoS ONE. 2015;10(3):e0119181.
   Google Scholar
• Kobayashi M, Matsumoto T, Ryuge S, et al. CAXII is a sero-diagnostic marker for lung cancer. PLoS ONE. 2012;7(3):e33952.
   Google Scholar
• Yoo CW, Nam B-H, Kim J-Y, et al. Carbonic anhydrase XII expression is associated with histologic grade of cervical cancer and superior radiotherapy outcome. Radiat Oncol. 2010;5:101.
   PubMed Web of Science ®Google Scholar
• Gieling RG, Williams KJ. Carbonic anhydrase IX as a target for metastatic disease. Bioorg Med Chem. 2013;21(6):1470–1476.
   PubMed Web of Science ®Google Scholar
• Sedlakova O, Svastova E, Takacova M, et al. Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Front Physiol. 2014;4:400.
   PubMed Web of Science ®Google Scholar
• Li Y, Tu C, Wang H, et al. Catalysis and pH control by membrane-associated carbonic anhydrase IX in MDA-MB-231 breast cancer cells. J Biol Chem. 2011;286(18):15789–15796.
   PubMed Web of Science ®Google Scholar
• Mahon BP, Pinard MA, McKenna R. Targeting carbonic anhydrase IX activity and expression. Mol. 2015;20(2):2323–2348.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Winum J-Y, Supuran CT, et al. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget. 2012;3(1):84–97.
   PubMed Web of Science ®Google Scholar
• Jogaitė V, Zubrienė A, Michailovienė V, et al. Characterization of human carbonic anhydrase XII stability and inhibitor binding. Bioorg Med Chem. 2013;21(6):1431–1436.
   PubMed Web of Science ®Google Scholar
• Chiche J, Brahimi-Horn MC, Pouysségur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med. 2010;14(4):771–794.
   PubMed Web of Science ®Google Scholar
• Chen X, Qian Y, Wu S. The warburg effect: evolving interpretations of an established concept. Free Radic Biol Med. 2015;79:253–263.
   PubMed Web of Science ®Google Scholar
• Gonzalez CD, Alvarez S, Ropolo A, et al. Autophagy, Warburg, and Warburg reverse effects in human cancer. BioMed Res Int. 2014;2014:926729.
   PubMedGoogle Scholar
• Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med. 2013;17(1):30–54.
   PubMed Web of Science ®Google Scholar
• Chiche J, Ilc K, Laferrière J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 2009;69(1):358–368.
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011;71(9):3364–3376.
   PubMed Web of Science ®Google Scholar
• Brynda J, Cigler P, Gruner B, et al. Carbonic anhydrase inhibitors and method of their production. US2014303390. 2014.
   Google Scholar
• Zimmerman C, Babich JW, Joyal JL, et al. Inhibitors of carbonic anhydrase IX. EP2823826. 2015.
   Google Scholar
• Ebbesen P, Supuran CT, Scozzafava A, et al. Carbonic anhydrase inhibitors. US2013053392. 2013.
   Google Scholar
• Supuran C, Scozzafava A, Masini E, et al. Carbonic anhydrase inhibitor comprising a dithiocarbamate. WO2013050426. 2013.
   Google Scholar
• Lambin P, Winum J-Y. Dual action carbonic anhydrase inhibitors. WO2015025283. 2015.
   Google Scholar
• Dubois L, Lambin P, Winum J-Y, et al. Cancer targeting using carbonic anhydrase isoform IX inhibitors. WO2012087115. 2012.
   Google Scholar
• Supuran C, Dedhar S, Carta F, et al. Carbonic anhydrase inhibitors with antimetastatic activity. CA2856812. 2012.
   Google Scholar
• Li Y, Wang H, Oosterwijk E, et al. Antibody-specific detection of CAIX in breast and prostate cancers. Biochem Biophys Res Commun. 2009;386(3):488–492.
   PubMed Web of Science ®Google Scholar
• Ahlskog JKJ, Schliemann C, Mårlind J, et al. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer. 2009;101(4):645–657.
   PubMed Web of Science ®Google Scholar
• Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38(4):489–494.
   PubMed Web of Science ®Google Scholar
• Marasco WA, Lo A, Xu C. Carbonic anhydrase IX (G250) antibodies and methods of use thereof. US2013336923. 2013.
   Google Scholar
• Marasco WA, Lo A, Xu C. Carbonic anhydrase IX (G250) antibodies and methods of use thereof. WO2007065027. 2007.
   Google Scholar
• Zeidler R, Battke C, Kremmer E, et al. Novel antibody to a carbonic anhydrase. AU2011250022. 2013.
   Google Scholar
• Renner C, Bauer S, Plesko M, et al. Antibodies directed against carbonic anhydrase IX and methods and uses thereof. WO2011139375. 2011.
   Google Scholar
• Pini R, Ratto F, Tatini F, et al. Assembly comprising an absorber of near infrared (nir) light covalently linked to an inhibitor of carbonic anhydrase. US2016015661. 2016.
   Google Scholar
• Babich JW, Zimmerman C, Joyal JL, et al. Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX. US2016009664. 2016.
   Google Scholar
• Kolb H, Chen G, Padgett H, et al. Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry. EP2468734. 2012.
   Google Scholar
• Najarian T, Tam PY, Wilson LF, et al. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors. US2016015730. 2016.
   Google Scholar
• Wang X, Schröder HC, Schlossmacher U, et al. Modulation of the initial mineralization process of SaOS-2 cells by carbonic anhydrase activators and polyphosphate. Calcif Tissue Int. 2014;94(5):495–509.
   PubMed Web of Science ®Google Scholar
• Müller WEG, Schröder HC, Wang X. Modulator of bone mineralization based on a combination of polyphosphate/carbonate and carbonic anhydrase activators. WO2015063249. 2015.
   Google Scholar
• Murakami H, Yamanishi H, Onji M. Method of inducing immune tolerance comprising administering carbonic anhydrase I. US2014170173. 2014.
   Google Scholar
• Mori K, Yamanishi H, Ikeda Y, et al. Oral administration of carbonic anhydrase I ameliorates murine experimental colitis induced by Foxp3−CD4+CD25− T cells. J Leukoc Biol. 2013;93(6):963–972.
   PubMed Web of Science ®Google Scholar
• Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. BioMed Res Int. 2014;2014:e967826.
   PubMed Web of Science ®Google Scholar
• Corripio GH, Vinas JL, Martinez AS. Use of carbonic anhydrase II for producing a drug. US2013101565. 2013.
   Google Scholar
• Cabiscol E, Levine RL, Carbonic Anhydrase III. Oxidative modification in vivo and loss of phosphate activity during aging. J Biol Chem. 1995;270(24):14742–14747.
   PubMed Web of Science ®Google Scholar
• Rodriguez VC. Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growrh factors of stem cells. US2011091576. 2011.
   Google Scholar
• Aggarwal M, Kondeti B, McKenna R. Insights towards sulfonamide drug specificity in α-carbonic anhydrases. Bioorg Med Chem. 2013;21(6):1526–1533.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Conway J. Carbonic anhydrase: its inhibitors and activators. Boca Raton (FL): CRC Press; 2004.
   Google Scholar
• Supuran CT, Winum J-Y. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Hoboken (NJ): John Wiley & Sons; 2009.
   Google Scholar
• Bozdag M, Ferraroni M, Nuti E, et al. Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: solution and X-ray crystallographic studies. Bioorg Med Chem. 2014;22(1):334–340.
   PubMed Web of Science ®Google Scholar
• Anderson AC. The process of structure-based drug design. Chem Biol. 2003;10(9):787–797.
   PubMed Web of Science ®Google Scholar
• Mandal S, Moudgil M, Mandal SK. Rational drug design. Eur J Pharmacol. 2009;625(1–3):90–100.
   PubMed Web of Science ®Google Scholar
• Oprea TI, Davis AM, Teague SJ, et al. Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci. 2001;41(5):1308–1315.
   PubMedGoogle Scholar
• Walters WP, Ajay MMA. Recognizing molecules with drug-like properties. Curr Opin Chem Biol. 1999;3(4):384–387.
   PubMed Web of Science ®Google Scholar
• Leeson P. Drug discovery: chemical beauty contest. Nature. 2012;481(7382):455–456.
   PubMed Web of Science ®Google Scholar
• Lomelino CL, Mahon BP, McKenna R, et al. Kinetic and X-ray crystallographic investigations on carbonic anhydrase isoforms I, II, IX and XII of a thioureido analog of SLC-0111. Bioorg Med Chem. 2016;24(5):976–981.
   PubMed Web of Science ®Google Scholar
• Congiu C, Onnis V, Deplano A, et al. Synthesis and carbonic anhydrase I, II, IX and XII inhibitory activity of sulfamates incorporating piperazinyl-ureido moieties. Bioorg Med Chem. 2015;23(17):5619–5625.
   PubMed Web of Science ®Google Scholar
• Congiu C, Onnis V, Deplano A, et al. Synthesis of sulfonamides incorporating piperazinyl-ureido moieties and their carbonic anhydrase I, II, IX and XII inhibitory activity. Bioorg Med Chem Lett. 2015;25(18):3850–3853.
   PubMed Web of Science ®Google Scholar